OVID

Insider Trades

Name	Value	Action	Price	Current Price
Alexander Margaret A.Director, Officer: President And CEO $17k11.7k shares SellFeb 23, 2026 $1.45 --
Rona Jeffrey ACBFO $12k8.5k shares SellFeb 23, 2026 $1.45 --
Levin Jeremy MDirector, Officer: CEO Disclosure amount unavailable71 shares BuyDec 11, 2025 -- --
Levin Jeremy MDirector, Officer: CEO $66k47.3k shares BuyDec 11, 2025 $1.40 --
Levin Jeremy MDirector, Officer: CEO $50k35.5k shares BuyDec 11, 2025 $1.40 --
Alexander Margaret A.President And COO $3.0k5.3k shares SellFeb 26, 2025 $0.56 --

News

globenewswire.comOvid Therapeutics to Participate in Upcoming Investor Conferencesglobenewswire.comJun 4

globenewswire.comOvid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directorsglobenewswire.comJun 3

globenewswire.comOvid Therapeutics Reports Business Updates and First Quarter 2026 Financial Resultsglobenewswire.comMay 12

proactiveinvestors.comAtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trialsproactiveinvestors.comApr 27

seekingalpha.comOvid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcriptseekingalpha.comApr 14

Trade OVID

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.

CEO: Margaret Alexander
IPO Date: May 5, 2017

Market Data

Open: $2.44
High: $2.49
Low: $2.27
Volume: 7.4M
Avg Volume: 2.5M
52W High: $3.11
52W Low: $0.285

Valuation

Market Cap: $299M
Enterprise Value: $207M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-38M
Revenue: $7.3M
Net Income: $-17M
Cash: $13M
Debt: $13M

Events

EarningsAug 12

EPS est. -0.12